SequelSEC

Aurinia Pharmaceuticals Inc. AUPH

Pharmaceutical Preparations · CIK 0001600620 · Fiscal year ends 1231

Revenue
$283.06M
Fiscal year ended 2025-12-31
Operating income
$104.91M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $283.06M and net income of $287.20M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Aurinia Pharmaceuticals Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aurinia Pharmaceuticals Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$283.06M$235.13M$175.51M$134.03M$45.60M$50.12M$318.00K$463.00K
Cost of revenue$32.66M$28.25M$14.15M$5.66M$1.09M$0$0Unavailable
Gross profit$250.39M$206.88M$161.36M$128.37M$44.51M$50.12M$318.00KUnavailable
Operating income$104.91M-$4.69M-$91.69M-$111.47M-$180.74M-$104.29M-$90.94M-$55.24M
Net income$287.20M$5.75M-$78.02M-$108.18M-$180.97M-$102.68M-$88.38M-$53.08M
Research & development$32.50M$20.78M$49.64M$44.99M$51.14M$50.33M$52.87M$41.38M
Weighted-average diluted sharesshares 138.70Mshares 146.19Mshares 143.24Mshares 141.92Mshares 129.37Mshares 118.47MUnavailableUnavailable
Pretax income$114.16M$7.45M-$77.47M-$106.35M-$180.21M-$102.77M-$88.24M-$53.01M
Income tax expense-$173.04M$1.70M$551.00K$1.83M$760.00K-$94.00K$144.00K$73.00K
Diluted EPS$2.07$0.04$-0.54$-0.76$-1.40$-0.87$-0.95Unavailable
Selling, general & administrativeUnavailableUnavailable$195.00M$196.40M$173.50M$97.30M$22.30MUnavailable
General & administrative$101.79M$172.03M$195.04M$196.37M$173.54M$97.27M$22.34M$13.69M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Aurinia Pharmaceuticals Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$80.16M$83.40M$48.76M$94.09M$231.64M$272.35M$306.02MUnavailable
Total assets$751.59M$550.64M$548.06M$470.86M$543.37M$463.66M$324.30MUnavailable
Current assets$491.97M$446.60M$424.80M$442.54M$513.32M$419.43M$315.14MUnavailable
Total liabilities$170.26M$173.17M$170.11M$65.42M$64.28M$55.91M$25.70MUnavailable
Current liabilities$93.72M$97.76M$77.19M$46.11M$40.65M$32.00M$11.30MUnavailable
Total equity incl. NCI$581.33M$377.48M$377.95M$405.44M$479.09M$407.75M$298.60M$135.72M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$45.69M$39.23M$39.70M$24.75M$19.33M$13.93M$0Unavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.31M$5.19M$4.33MUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Aurinia Pharmaceuticals Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow$135.66M$44.39M-$33.46M-$79.53M-$157.69M-$69.86M-$63.58M-$51.61M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$32.77M$39.26M-$6.71M-$60.63M-$103.87M-$158.19M$7.78M-$65.00K
Financing cash flow-$106.11M-$49.09M-$5.13M$2.43M$221.11M$194.38M$243.85M$4.01M
Net change in cash-$3.22M$34.56M-$45.30M-$137.73M-$40.45M-$33.67M$188.05M-$47.66M
Stock-based compensation$14.68M$31.60M$45.31M$32.30M$31.24M$17.45M$7.41M$6.86M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$98.16M$40.24M$0$0UnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$19.45M$19.44M$11.65M$2.71M$2.76M$1.37MUnavailableUnavailable

Derived

Aurinia Pharmaceuticals Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin88.5%88.0%91.9%95.8%97.6%100.0%100.0%Unavailable
Operating margin37.1%-2.0%-52.2%-83.2%-396.3%-208.1%-28598.4%-11930.9%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue5.2%13.4%25.8%24.1%68.5%34.8%2331.4%1481.6%
Current ratio5.25x4.57x5.50x9.60x12.63x13.11x27.90xUnavailable
Revenue YoY growth20.4%34.0%31.0%193.9%-9.0%15660.4%-31.3%Unavailable
Net margin101.5%2.4%-44.5%-80.7%-396.8%-204.9%-27794.0%-11464.1%
R&D / revenue11.5%8.8%28.3%33.6%112.1%100.4%16624.5%8937.8%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate-151.6%22.8%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AUPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.